Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Dihydroergotamine
Drug ID BADD_D00671
Description A 9,10alpha-dihydro derivative of [ergotamine]. Dihydroergotamine is used as an abortive therapy for migraines.[L38469] Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. Recent improvements have been made in the design of intranasal delivery devices allowing for greater delivery of dihydroergotamine solution to the vasculature-rich upper nasal cavity.[A239569] The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution formulated at 75% of the strength of the existing intranasal product.
Indications and Usage For the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes.
Marketing Status Prescription
ATC Code N02CA01
DrugBank ID DB00320
KEGG ID D07837
MeSH ID D004087
PubChem ID 10531
TTD Drug ID D0V3ZA
NDC Product Code 47848-052; 69238-1606
Synonyms Dihydroergotamine | Clavigrenin | D-Tamin Retard L.U.T. | D Tamin Retard L.U.T. | DET MS | DHE-45 | DHE 45 | DHE45 | D.H.E. 45 | DHE-Puren | DHE Puren | DHE-Ratiopharm | DHE Ratiopharm | Dihydroergotamin AL | Dihydroergotamine Mesylate | Mesylate, Dihydroergotamine | Dihydroergotamine Methanesulfonate | Methanesulfonate, Dihydroergotamine | Dihytamin | Erganton | Ergomimet | Ergont | Ergotam Von Ct | Von Ct, Ergotam | Ikaran | Migranal | Dihydergot | Dihydroergotamine-Sandoz | Dihydroergotamine Sandoz | Orstanorm | Seglor | Agit | Tamik | Verladyn | Angionorm
Chemical Information
Molecular Formula C33H37N5O5
CAS Registry Number 511-12-6
SMILES CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CC6C(CC7=CNC8=CC=CC6=C78)N (C5)C
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Agitation17.02.05.012; 19.06.02.001--
Angina pectoris02.02.02.002; 24.04.04.002--
Anxiety19.06.02.002--
Aphonia17.02.08.009; 19.19.01.002; 22.02.05.024--
Application site reaction08.02.01.006; 12.07.01.006--Not Available
Arteriospasm coronary02.02.02.005; 24.04.04.005--Not Available
Arthralgia15.01.02.001--
Asthenia08.01.01.001--Not Available
Bladder pain20.02.02.001--Not Available
Body temperature increased13.15.01.001--Not Available
Bronchitis11.01.09.001; 22.07.01.001--
Bronchospasm10.01.03.012; 22.03.01.004--
Cerebrovascular accident17.08.01.007; 24.03.05.001--
Chills08.01.09.001; 15.05.03.016--
Cold sweat08.01.03.024; 23.02.03.002--Not Available
Confusional state17.02.03.005; 19.13.01.001--
Conjunctivitis06.04.01.002; 11.01.06.012--
Cystitis11.01.14.001; 20.03.02.002--
Depressed level of consciousness17.02.04.002--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Disturbance in attention17.03.03.001; 19.21.02.002--
Dizziness02.01.02.004; 17.02.05.003; 24.06.02.007--
Dry mouth07.06.01.002--
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Dyspnoea02.01.03.002; 22.02.01.004--
Ear pain04.03.01.003--
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages